Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0615 ET – Merck KGaA expects its 2024 sales target to come in ...

Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...